485 | | - cryoEM: drivers of interest are that it is increasingly important in structural biology in general, and NIAID has a core facility with a new and enthusiastic director, James Cherry. |
486 | | - VR?: Still very much of interest. Somewhat of a pause recently due to equipment requirements if used remotely, and pandemic-related decrease in users of their own VR facility. |
| 485 | - cryoEM: Drivers of interest are that it is increasingly important in structural biology in general, and NIAID has a core facility with a new and enthusiastic director, James Cherry. |
| 486 | - VR: Still very much of interest. Somewhat of a pause recently due to equipment requirements if used remotely, and pandemic-related decrease in users of their own VR facility. |
488 | | - medical imaging, how much emphasis should we place on ChimeraX development in this area? Darrell: mainly interested in the context of VR, shared VR meetings. Phil: there may be fertile ground for ChimeraX development is segmentation in 3D in VR. 2D tools not so great for segmentation. Could also apply to 3D light microscopy, EM tomography, ... |
489 | | - !AlphaFold: we think many people are using these capabilities, not just new prediction but also fetch and sequence search of the database of existing structures. The database itself doesn't have this capability, so the ChimeraX interface is often more convenient. |
490 | | TomG: Google is not treating this as a product, it's more like academic software with little incentive for improvement. Should we include this !AlphaFold usability stuff in the contract? Darrell: worthwhile, but consider whether it's a better fit for the R01. It could possibly be in the contract, as our mission includes democratizing the latest tools and methods. TomG: maybe better wording than "democratizing" is "diversity, equity, inclusion." |
| 488 | - Medical imaging: How much emphasis should we place on ChimeraX development in this area? Darrell: mainly interested in the context of VR, shared VR meetings. Phil: there may be fertile ground for ChimeraX development is segmentation in 3D in VR. 2D tools not so great for segmentation. Could also apply to 3D light microscopy, EM tomography, ... |
| 489 | - !AlphaFold: we think many people are using these capabilities, not just new prediction but also fetch and sequence search of the database of existing structures. The database itself doesn't have this capability, so the ChimeraX interface is often more convenient. TomG: Google is not treating this as a product, it's more like academic software with little incentive for improvement. Should we include this !AlphaFold usability stuff in the contract? Darrell: worthwhile, but consider whether it's a better fit for the R01. It could possibly be in the contract, as our mission includes democratizing the latest tools and methods. TomG: maybe better wording than "democratizing" is "diversity, equity, inclusion." |